Please enter the email address you used to register, then we will send you a link to choose a new password
Oppenheimer analyst Jay Olson maintains Galecto (NASDAQ:GLTO) with a Outperform and lowers the price target from $10 to $9.
With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as foll...
Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis...
Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis...
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Galecto (NASDAQ:GLTO) from Buy to Neutral.
Gainers